American Society of Anesthesiologists Announces Heron Therapeutics as Industry Supporter for Seventh Year

CHICAGO – The American Society of Anesthesiologists (ASA) today announced Heron Therapeutics (Nasdaq: HRTX) has rejoined ASA’s Industry Supporter Program for a seventh consecutive year, supporting the Society’s more than 59,000 anesthesiologist members to improve patient care for the treatment of pain following surgery and postoperative nausea and vomiting (PONV).

“We couldn’t be more pleased to continue our partnership with Heron Therapeutics through the ASA Industry Supporter Program,” said ASA President Donald E. Arnold, M.D., FACHE, FASA. “Heron’s patient-centered focus on reducing reliance on opioids for acute pain through non-opioid alternatives, and solutions for PONV, are helping anesthesiologists and other health care professionals to provide better ways to treat patients in the acute surgical care setting. Our collaboration allows us to work together to provide opportunities to advance education and innovation in these areas.”

As an Industry Supporter, Heron is helping to establish a strong, mutually-beneficial relationship with the anesthesiology community, strengthen collaboration between anesthesiologists and industry, and add to the value the Society provides to patients and the public, while providing invaluable year-round support of ASA programs and priorities related to non-opioid alternatives and PONV treatment options.

Industry Supporters have unique opportunities to inform strategic dialogue with leaders in anesthesiology from around the world and during major ASA events including the ANESTHESIOLOGY^® annual meeting and ADVANCE conference.

“Our partnership with the ASA represents a strategic extension of Heron’s ongoing commitment to innovation in perioperative care,” said Craig Collard, chief executive officer of Heron Therapeutics. “Together with ASA, we see significant potential to drive meaningful improvements in patient outcomes and the overall surgical experience. This collaboration not only reinforces our shared mission to elevate standards of care but also unlocks new opportunities in research, technology, and clinical excellence. We’re excited to build on this momentum and further a partnership centered around putting patients first.”

Launched in 2010, ASA’s Industry Supporter Program is limited to 10 organizations. Participation is intended for companies who want to stand apart by showcasing high-level commitment to the education of anesthesiologists, the anesthesia care team and advancement of the specialty.

About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

About the American Society of Anesthesiologists
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 59,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about how anesthesiologists help ensure patient safety, visit asahq.org/madeforthismoment. Follow ASA on Facebook, X, Instagram, Bluesky, and LinkedIn.

# # #